Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase I/II Study of Sequential Epigenetic and Immune Targeting in Combination With Nab-Paclitaxel/Gemcitabine in Patients With Advanced Pancreatic Ductal Adenocarcinoma.

NCT04257448 is registered in ClinicalTrials.gov with GWT-TUD GmbH as lead sponsor.

NCT NCT04257448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04257448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase I/II Study of Sequential Epigenetic and Immune Targeting in Combination With Nab-Paclitaxel/Gemcitabine in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
Lead sponsor
GWT-TUD GmbH
Phase
Phase 1/2
Overall status
Completed
Start date
May 25, 2020
Completion date
July 2, 2024
Enrollment
75 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas cancer, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma